Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.52 |
| ▸ | MTOR | P42345 | 4/20 | 0.52 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | PIK3C3 | Q8NEB9 | 5/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3105712 | 0.87 | PIK3CA (0.54) | PIK3CAMTORAKT1PIK3C3MAP4K4 | |
| SCHEMBL3114666 | 0.84 | PIK3CA (0.44) | PIK3CAMTORAKT1PIK3C3MAP4K4 | |
| SCHEMBL3122672 | 0.84 | PIK3CA (0.46) | PIK3CAMTORAKT1PIK3C3MAP4K4 | |
| SCHEMBL3112346 | 0.83 | PIK3CA (0.43) | PIK3CAMTORAKT1PIK3C3MAP4K4 | |
| SCHEMBL729441 | 0.83 | PIK3CA (0.58) | PIK3CAAKT1PIK3C3MAPK10ALOX5AP | |
| SCHEMBL3113694 | 0.82 | PIK3CA (0.43) | PIK3CAMTORAKT1 | |
| SCHEMBL731357 | 0.81 | PIK3CA (0.77) | PIK3CAMTORAKT1PIK3C3MAPK10 | |
| SCHEMBL3074529 | 0.79 | PIK3CA (0.47) | PIK3CAAKT1PIK3C3ALOX5APFEN1 | |
| SCHEMBL3120579 | 0.79 | PIK3CA (0.42) | PIK3CAMTORAKT1PIK3C3MAPK10 | |
| SCHEMBL731719 | 0.75 | PIK3CA (0.64) | PIK3CAMTORAKT1PIK3C3ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | ADAMS NICHOLAS D | 2009-01-15 | — | — | US | disclosed |
| WO-2008157191-A2 | QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179144-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, AKT3 | PIK3CA 18/4885MTOR 150/4885AKT1 77/4885 |
| US-20090018131-A1 | QUINAZOLINE DERIVATIVES AS P13 KINASE INHIBITORS | JAK3, PI4KA, AKT3 | PIK3CA 18/4885MTOR 150/4885AKT1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.